KMTS · CIK 0001877184
What Kestra Medical Technologies, Ltd. told the SEC could break it.
Kestra Medical's disclosures revolve around its dependence on a single product and on the payors who reimburse it. Nearly all of its revenue comes from directly billing third-party payors — Medicare, Medicaid and private insurers — for leasing its ASSURE wearable cardioverter defibrillator, reimbursed under a Medicare capped-rental code, so any adverse change in coverage or rates would hit revenue directly. That revenue rides almost entirely on the one ASSURE / Cardiac Recovery System line in a market long served by a single incumbent, making a clinical, regulatory or reimbursement setback existential. As a not-yet-profitable company, it also carries an expensive Perceptive term loan (originally 14.5% interest) and relies on a limited number of third-party manufacturers to build and recondition the device.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- nearly all revenue from third-party payor reimbursement (Medicare HCPCS K0606, Medicaid, private payors)high
Kestra derives nearly all revenue from direct billing of third-party payors — Medicare, Medicaid and private payors — for leasing its ASSURE WCD; its ASSURE WCD is reimbursed under Medicare capped-rental HCPCS code K0606 (~$3,519/month, months 1-3). Adverse changes to coverage, code verification or reimbursement rates would directly impair revenue.
“We derive nearly all our revenue from the direct billing of various third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations, for the lease of our ASSURE WCD to patients as part of our Cardiac Recovery System platform.”
SEC filing →As of 2025
Liquidity & debt
- high-cost Perceptive Credit term loan (14.5% rate, warrants, covenants) at a pre-profitability companymedium
Kestra, not yet profitable, carries an expensive term loan from Perceptive Credit (originally bearing 14.5% interest, with lender warrants and restrictive covenants); incurrence of such indebtedness raises fixed-payment obligations and may require restrictive covenants, while additional equity/convertible financing would dilute shareholders.
“The Term Loan originally bore interest on outstanding balances of 14.5 % per ann”
SEC filing →As of 2025
Other disclosures
- single-product (ASSURE WCD) concentration in a market with a single incumbent competitormedium
Kestra's revenue depends almost entirely on a single product line — the ASSURE WCD / Cardiac Recovery System — in the wearable-cardioverter-defibrillator market, which until its July 2021 FDA approval was served by a single supplier (incumbent ZOLL). Product/competitive concentration means a clinical, regulatory or reimbursement setback to ASSURE would be existential.
“until the ASSURE WCD received FDA approval in July of 2021, the market was served by a single supplier.”
SEC filing →As of 2025
Supplier concentration
- single/limited third-party manufacturers and suppliers for ASSURE WCD components and reconditioningmedium
Kestra depends on a small number of third-party suppliers and contract manufacturers to make and recondition its ASSURE wearable cardioverter defibrillator (WCD) and its components, relying on a single or limited number of suppliers for certain components; an interruption in these manufacturing/reconditioning services could cause supply shortages and harm the business.
“we depend on a limited number of third-party suppliers and contract manufacturers to manufacture and recondition our ASSURE WCD and its components, which could make us vulnerable to supply shortages and price fluctuations that could harm our business”
SEC filing →As of 2025
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch